Experts Welcome Adjuvant Nivolumab for Melanoma

The PD-1 inhibitor nivolumab was recently approved by the FDA for adjuvant use in completely resected stage III or IV melanoma, a move welcomed by experts in the field.
Medscape Medical News

http://ift.tt/2DizB8V